InhaleRx Past Earnings Performance

Past criteria checks 0/6

InhaleRx has been growing earnings at an average annual rate of 4.6%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 57.9% per year.

Key information

4.6%

Earnings growth rate

28.7%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate57.9%
Return on equityn/a
Net Margin-85.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How InhaleRx makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:IRX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-110
31 Mar 241-111
31 Dec 231-111
30 Sep 231-212
30 Jun 230-212
31 Mar 230-211
31 Dec 220-211
30 Sep 220-211
30 Jun 220-111
31 Mar 220-110
31 Dec 210-110
30 Sep 210-110
30 Jun 210-110
31 Mar 210-110
31 Dec 200-110
30 Sep 200-210
30 Jun 200-210
31 Mar 200-210
31 Dec 190-220
30 Sep 190-220
30 Jun 190-220
31 Mar 190-220
31 Dec 180-220
30 Sep 180-220
30 Jun 181-220
31 Mar 181-320
31 Dec 170-330
31 Dec 160000

Quality Earnings: IRX is currently unprofitable.

Growing Profit Margin: IRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IRX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare IRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).


Return on Equity

High ROE: IRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 14:34
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InhaleRx Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution